|
I. Platinum-based agents
|
|
E-GEOD-38122 [103]
|
Hepatocyte carcinoma
|
24
|
3
|
3
|
|
GSE47980 [104]
|
Melanoma
|
24
|
9
|
9
|
|
GSE38545
|
Ovarian cancer
|
24
|
3
|
3
|
|
GSE13525 [105]
|
Ovarian cancer
|
24
|
2
|
2
|
|
E-GEOD-8057 [106]
|
Ovarian cancer
|
24
|
4
|
4
|
|
GSE51952 [107]
|
Hepatocyte carcinoma
|
24
|
3
|
3
|
|
GSE66493
|
Glioblastoma
|
24
|
3
|
3
|
|
GDS3910 [108]
|
Breast cancer
|
11
|
2
|
2
|
|
E-MTAB-3645 [109]
|
Ovarian cancer
|
72
|
3
|
3
|
|
II. Paclitaxel
|
|
E-GEOD-50831 [110]
|
Ovarian cancer
|
24
|
63
|
63
|
|
E-GEOD-50830 [110]
|
Endometrial adenocarcinoma
|
24
|
55
|
57
|
|
E-GEOD-50811 [110]
|
Breast cancer
|
24
|
79
|
81
|
|
III. Irradiation (two meta-analyses for cancer and embryonic cells)
|
|
E-GEOD-59732 [111]
|
Breast cancer
|
24
|
48
|
48
|
|
E-GEOD-59861 [112]
|
Skin fibroblasts
|
0, 3, 6, 12, 24
|
4
|
12
|
|
IV. Hypoxia
|
|
E-GEOD-18494 [113]
|
Hepatocyte carcinoma, glioblastoma, breast cancer
|
12
|
9
|
9
|
|
E-GEOD-53012 [114]
|
Prostate cancer, ovarian cancer, melanoma
|
72
|
9
|
9
|
|
E-MTAB-3645 [109]
|
Ovarian cancer
|
72
|
3
|
3
|
|
E-GEOD-17188 [115]
|
Breast cancer
|
24
|
4
|
4
|
|
V. Tyrosine kinase inhibitors
|
|
E-TABM-585 [116]
|
Lung cancer
|
20
|
21
|
27
|
|
VI. Topoisomerase inhibitors
|
|
E-GEOD-47013 [117]
|
Multiple myeloma
|
–
|
3
|
3
|
|
E-GEOD-13477 [118]
|
Breast cancer
|
24
|
2
|
2
|
|
E-GEOD-19638 [119]
|
Breast cancer
|
–
|
2
|
2
|
|
E-GEOD-39870 [120]
|
Breast cancer
|
–
|
3
|
3
|
|
Splicing analysis
|
|
GSE69405 [37]
|
Lung adenocarcinoma
|
48
|
12
|
12
|
|
GSE89127 [34]
|
Gastric carcinoma, lung adenocarcinoma, melanoma, urinary bladder carcinoma
|
48
|
18
|
18
|
|
Spliceostatin
|
|
GSE72156 [58]
|
Cervical cancer
|
–
|
3
|
3
|
|
Pladienolide
|
|
E-GEOD-67770 [57]
|
Ovarian cancer
|
–
|
2
|
2
|
